Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Initial therapy for chronic myelogenous leukemia: playing the odds

S J Lee, C Anasetti, M M Horowitz

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |September 17, 1998
    PubMed
    Summary

    Newly diagnosed patients with chronic myeloid leukemia (CML) have improved life expectancy. Evidence-based analysis of transplant survival and interferon response can guide optimal first-line therapy selection.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

    Bone marrow transplantation·2017
    Same author

    Parent versus child donor perceptions of the bone marrow donation experience.

    Bone marrow transplantation·2017
    Same author

    Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.

    Bone marrow transplantation·2017
    Same author

    Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.

    Bone marrow transplantation·2017
    Same author

    Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors.

    Bone marrow transplantation·2016
    Same author

    Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.

    Bone marrow transplantation·2016

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Therapeutics

    Background:

    • Chronic myeloid leukemia (CML) treatment has advanced, improving patient life expectancy.
    • Optimal first-line therapy selection for newly diagnosed CML remains controversial.
    • Balancing curative potential with treatment toxicity is crucial for initial therapy decisions.

    Discussion:

    • An evidence-based approach weighing transplant survival and interferon response is proposed for guiding CML therapy.
    • This strategy aims to triage suitable patients to curative transplant options.
    • Patients less likely to benefit from transplantation are advised less toxic, yet beneficial, non-transplant therapies.

    Key Insights:

    • Personalized medicine in CML requires considering individual patient factors beyond transplant and interferon response.

    Related Experiment Videos

  • Shared decision-making between clinicians and patients is essential for optimal treatment selection.
  • Coexisting medical conditions and personal values significantly influence the choice of initial CML therapy.

    • Outlook:

    • Further research into predictive biomarkers for transplant success and interferon efficacy is warranted.
    • Developing refined risk-stratification models will enhance personalized CML treatment strategies.
    • Continued evaluation of long-term outcomes for both transplant and non-transplant therapies is necessary.